Appendix 1

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix 1: National Comprehensive Cancer Network (NCCN) criteria for assessing risk of disease progression categories.7

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
</table>
| Clinically localised disease: very low risk for disease progression | T1c  
Gleason score ≤ 6  
PSA <10 ng/mL  
Fewer than 3 prostate biopsy cores positive, ≤ 50% cancer in each core  
PSA density <0.15 ng/mL/g |
| Clinically localised disease: low risk for disease progression | Clinical stage T1-T2a  
T1 Clinically inapparent tumour not palpable or visible by imaging  
• T1a Tumour incidental histological finding in 5% or less of tissue resected  
• T1b Tumour incidental histological finding in more than 5% of tissue resected  
• T1c Tumour identified by needle biopsy (e.g. because of elevated prostate-specific antigen [PSA] level)
T2 Tumour confined within the prostate  
• T2a Tumour involves one half of one lobe or less  
AND Gleason score* <7  
AND Prostate specific antigen (PSA) level < 10ng/mL |
| Clinically localised disease: intermediate risk for disease progression | Clinical stage T2b-T2c  
T2 Tumour confined within the prostate  
• T2b Tumour involves more than half of one lobe, but not both lobes  
• T2c Tumour involves both lobes  
OR Gleason score = 7  
OR PSA level 10-20ng/mL |
| Clinically localised disease: high risk for disease progression | Clinical stage T3a  
T3 Tumour extends through the prostatic capsule  
• T3a Extracapsular extension (unilateral or bilateral) including microscopic bladder neck Involvement  
OR Gleason score 8-10  
OR PSA>20ng/mL |
| Locally advanced disease: very high risk for disease progression | Clinical stage T3b-4 N0 M0  
T3 Tumour extends through the prostatic capsule  
• T3b Tumour invades seminal vesicle(s)  
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, levator muscles, and/or pelvic wall  
N0 No regional lymph node metastasis  
M0 No distant metastasis |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Metastatic disease | Any clinical stage N1 M1  
N1 Regional lymph node metastasis  
M1 Distant metastasis |

*Gleason score is the standard for grading adenocarcinoma of the prostate on core biopsy specimens. The Gleason score is the sum of the two most common patterns of tumour growth found. The Gleason ranges from 2-10, with 10 being the most aggressive.*